Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.530
+0.020 (1.32%)
Feb 5, 2026, 9:41 AM EST - Market open
Pyxis Oncology Employees
Pyxis Oncology had 44 employees as of December 31, 2024. The number of employees decreased by 6 or -12.00% compared to the previous year.
Employees
44
Change
-6
Growth
-12.00%
Revenue / Employee
$64,091
Profits / Employee
-$2,206,500
Market Cap
95.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 44 | -6 | -12.00% |
| Sep 30, 2024 | 54 | -13 | -19.40% |
| Jun 30, 2024 | 55 | -17 | -23.61% |
| Mar 31, 2024 | 51 | -22 | -30.14% |
| Dec 31, 2023 | 50 | -25 | -33.33% |
| Sep 30, 2023 | 67 | -6 | -8.22% |
| Jun 30, 2023 | 72 | 5 | 7.46% |
| Mar 31, 2023 | 73 | 9 | 14.06% |
| Dec 31, 2022 | 75 | 19 | 33.93% |
| Sep 30, 2022 | 73 | 28 | 62.22% |
| Jun 30, 2022 | 67 | 29 | 76.32% |
| Mar 31, 2022 | 64 | 26 | 68.42% |
| Dec 31, 2021 | 56 | - | - |
| Sep 30, 2021 | 45 | - | - |
| Jun 30, 2021 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Champions Oncology | 213 |
| Seer, Inc. | 134 |
| Artiva Biotherapeutics | 106 |
| Fortress Biotech | 101 |
| aTyr Pharma | 65 |
| ALX Oncology Holdings | 44 |
| Cognition Therapeutics | 28 |
PYXS News
- 2 days ago - Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity - GlobeNewsWire
- 6 weeks ago - Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
- 6 weeks ago - Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript - Seeking Alpha
- 7 weeks ago - Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
- 3 months ago - Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings - GlobeNewsWire
- 4 months ago - Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - GlobeNewsWire